|
 |
Business Strategy
|
APS is biopharmaceutical company with a strong and balanced product portfolio of novel therapies for cancer and inflammatory diseases. In addition to improving patients' lives around the world, APS is committed to generating value for its investors. APS develops, for rapid commercialization, high-value, topically administered peptides and supportive cancer care drug product candidates. The company’s strategy is to identify product candidates and to take them from an early stage of development into clinical trials with appropriate partners for multiple clinical indications and geographic regions across the world.
APS has built a strong drug platform based on naturally occurring human growth factors which have led to an expanding product portfolio. Our products focus specifically on significant unmet medical needs such as chemotherapy and radiation induced mucositis, radiation induced proctitis, inflammatory bowel disease and ulcerative colitis. Our products have the potential to treat multiple indications and work safely in concert with other drugs to help simplify overall cancer care.
- Our lead product AP002 is a best in class peptide, focused on preventing oral mucositis in head and neck cancers. AP002 can be rapidly developed to provide a solution for all solid tumors. AP002 is presently in late preclinical development.
- APS other product opportunities currently include commercialization of other peptide derivatives to treat CNS indications such as Alzheimer’s and Parkinson’s.
|
|
Business Strategy